期刊
PROSTAGLANDINS & OTHER LIPID MEDIATORS
卷 106, 期 -, 页码 45-52出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2013.09.002
关键词
Prostaglandin F-2 alpha; Alzheimer's disease; A beta clearance; Inflammation; Microglia
资金
- National Science & Technology Major Project Key New Drug Creation. and Manufacturing Program [2012ZX09103101-018, 2012ZX09301001-004]
- State Key Program of Basic Research of China [2010CB912501]
- Science Foundation of Shanghai [12431900300]
Alzheimer's disease (AD) is characterized by extracellular deposit of beta-amyloid (A beta) and accumulation of intracellular neurofibrillary tangles in the brain. Prostaglandin F-2 alpha, (PGF(2 alpha)) is one of the major metabolites of arachidonic acid (AA), and plays essential roles in a series of key physiological processes like luteolysis and parturition. Additionally, PGF(2 alpha) is also involved in the regulation of chronic and acute inflammation processes. Recent clinical studies have revealed the high content of PGE(2 alpha) metabolite, 15-keto-dihydro-PGF(2 alpha) in AD patients, implying the activation of in vivo PGF(2 alpha) biosynthesis. However, the mechanism underlying the involvement of PGF(2 alpha) in the progression of AD still remains unclear. Here we discovered that PGF(2 alpha) selectively antagonized LXR (liver X receptors)/RXR (retinoid X receptor alpha) and RXR/RXR dimers. Cell based assays indicated that PGF(2 alpha) effectively antagonized the activation of LXR agonist (t0901317) on A beta clearance via inhibiting apolipoprotein E (apoE) expression, and cell apoptosis alleviation by accelerating inflammatory response to A beta or Lipopolysaccharide (LPS) in microglia. Therefore, our current findings have addressed the potential association of PGF(2 alpha) with AD progression, and highlighted that inhibition of PGF(2 alpha) biosynthesis might be a useful therapeutic strategy against AD. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据